Building on the promising results of its ChAdOx1 nCoV-19 vaccine against Covid-19 in a Phase I study, University of Oxford researchers “are now initiating studies to evaluate how well the vaccine induces immune responses in older adults, and to test whether it can provide protection in the wider population,” explains Oxford Vaccine Group head Professor Andrew Pollard.

The researchers are looking to recruit more than 10,000 adults and children into the Phase II and III studies. The participants will be randomised to receive either the ChAdOx1 nCoV-19 vaccine or a licensed vaccine as a control.

This research is being supported by AstraZeneca “to accelerate the development and globalisation of this potential new vaccine against COVID-19 infection,” noted AstraZeneca subsidiary BioPharmaceuticals R&D executive vice-president Mene Pangalos. “The speed at which this new vaccine has advanced into late-stage clinical trials is testament to Oxford’s ground-breaking scientific research.”